DNA degradation test predicts success in whole-genome amplification from diverse clinical samples

Fengfei Wang, Lilin Wang, Christine Briggs, Ewa Sicinska, Sandra M. Gaston, Harvey Mamon, Matthew H. Kulke, Raffaella Zamponi, Massimo Loda, Elizabeth Maher, Shuji Ogino, Charles S. Fuschs, Jin Li, Carlos Hader, G. Mike Makrigiorgos

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The need to apply modern technologies to analyze DNA from diverse clinical samples often stumbles on suboptimal sample quality. We developed a simple approach to assess DNA fragmentation in minute clinical samples of widely different origin and the likelihood of success of degradation-tolerant whole genome amplification (restriction and circularization-aided rolling circle amplification, RCA-RCA) and subsequent polymerase chain reaction (PCR). A multiplex PCR amplification of four glyceraldehyde-3-phosphate dehydrogenase amplicons of varying sizes was performed using genomic DNA from clinical samples, followed by size discrimination on agarose gel or fluorescent denaturing high-performance liquid chromatography (dHPLC). RCA-RCA followed by real-time PCR was also performed, for correlation. Even minimal quantities of longer PCR fragments (∼ 300 to 400 bp), visible via high-sensitivity fluorescent dHPLC or agarose gel, were essential for the success of RCA-RCA and subsequent PCR-based assays. dHPLC gave a more accurate correlation between DNA fragmentation and sample quality than agarose gel electrophoresis. Multiplex-PCR-dHPLC predicted correctly the likelihood of assay success in formalin-fixed, paraffin-embedded samples fixed under controlled conditions and of different ages, in laser capture microdissection samples, in tissue print micropeels, and plasma-circulating DNA. Estimates of the percent information retained relative to snap-frozen DNA are derived for real-time PCR analysis. The assay is rapid and convenient and can be used widely to characterize DNA from any clinical sample of unknown quality.

Original languageEnglish (US)
Pages (from-to)441-451
Number of pages11
JournalJournal of Molecular Diagnostics
Volume9
Issue number4
DOIs
StatePublished - Sep 2007

Fingerprint

Genome
High Pressure Liquid Chromatography
DNA
Multiplex Polymerase Chain Reaction
DNA Fragmentation
Polymerase Chain Reaction
Sepharose
Real-Time Polymerase Chain Reaction
Gels
Laser Capture Microdissection
Glyceraldehyde-3-Phosphate Dehydrogenases
Agar Gel Electrophoresis
Paraffin
Sample Size
Formaldehyde
Technology

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Wang, F., Wang, L., Briggs, C., Sicinska, E., Gaston, S. M., Mamon, H., ... Makrigiorgos, G. M. (2007). DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. Journal of Molecular Diagnostics, 9(4), 441-451. https://doi.org/10.2353/jmoldx.2007.070004

DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. / Wang, Fengfei; Wang, Lilin; Briggs, Christine; Sicinska, Ewa; Gaston, Sandra M.; Mamon, Harvey; Kulke, Matthew H.; Zamponi, Raffaella; Loda, Massimo; Maher, Elizabeth; Ogino, Shuji; Fuschs, Charles S.; Li, Jin; Hader, Carlos; Makrigiorgos, G. Mike.

In: Journal of Molecular Diagnostics, Vol. 9, No. 4, 09.2007, p. 441-451.

Research output: Contribution to journalArticle

Wang, F, Wang, L, Briggs, C, Sicinska, E, Gaston, SM, Mamon, H, Kulke, MH, Zamponi, R, Loda, M, Maher, E, Ogino, S, Fuschs, CS, Li, J, Hader, C & Makrigiorgos, GM 2007, 'DNA degradation test predicts success in whole-genome amplification from diverse clinical samples', Journal of Molecular Diagnostics, vol. 9, no. 4, pp. 441-451. https://doi.org/10.2353/jmoldx.2007.070004
Wang, Fengfei ; Wang, Lilin ; Briggs, Christine ; Sicinska, Ewa ; Gaston, Sandra M. ; Mamon, Harvey ; Kulke, Matthew H. ; Zamponi, Raffaella ; Loda, Massimo ; Maher, Elizabeth ; Ogino, Shuji ; Fuschs, Charles S. ; Li, Jin ; Hader, Carlos ; Makrigiorgos, G. Mike. / DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. In: Journal of Molecular Diagnostics. 2007 ; Vol. 9, No. 4. pp. 441-451.
@article{48b209dcf5834e52b97063c2b6e4dc65,
title = "DNA degradation test predicts success in whole-genome amplification from diverse clinical samples",
abstract = "The need to apply modern technologies to analyze DNA from diverse clinical samples often stumbles on suboptimal sample quality. We developed a simple approach to assess DNA fragmentation in minute clinical samples of widely different origin and the likelihood of success of degradation-tolerant whole genome amplification (restriction and circularization-aided rolling circle amplification, RCA-RCA) and subsequent polymerase chain reaction (PCR). A multiplex PCR amplification of four glyceraldehyde-3-phosphate dehydrogenase amplicons of varying sizes was performed using genomic DNA from clinical samples, followed by size discrimination on agarose gel or fluorescent denaturing high-performance liquid chromatography (dHPLC). RCA-RCA followed by real-time PCR was also performed, for correlation. Even minimal quantities of longer PCR fragments (∼ 300 to 400 bp), visible via high-sensitivity fluorescent dHPLC or agarose gel, were essential for the success of RCA-RCA and subsequent PCR-based assays. dHPLC gave a more accurate correlation between DNA fragmentation and sample quality than agarose gel electrophoresis. Multiplex-PCR-dHPLC predicted correctly the likelihood of assay success in formalin-fixed, paraffin-embedded samples fixed under controlled conditions and of different ages, in laser capture microdissection samples, in tissue print micropeels, and plasma-circulating DNA. Estimates of the percent information retained relative to snap-frozen DNA are derived for real-time PCR analysis. The assay is rapid and convenient and can be used widely to characterize DNA from any clinical sample of unknown quality.",
author = "Fengfei Wang and Lilin Wang and Christine Briggs and Ewa Sicinska and Gaston, {Sandra M.} and Harvey Mamon and Kulke, {Matthew H.} and Raffaella Zamponi and Massimo Loda and Elizabeth Maher and Shuji Ogino and Fuschs, {Charles S.} and Jin Li and Carlos Hader and Makrigiorgos, {G. Mike}",
year = "2007",
month = "9",
doi = "10.2353/jmoldx.2007.070004",
language = "English (US)",
volume = "9",
pages = "441--451",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "4",

}

TY - JOUR

T1 - DNA degradation test predicts success in whole-genome amplification from diverse clinical samples

AU - Wang, Fengfei

AU - Wang, Lilin

AU - Briggs, Christine

AU - Sicinska, Ewa

AU - Gaston, Sandra M.

AU - Mamon, Harvey

AU - Kulke, Matthew H.

AU - Zamponi, Raffaella

AU - Loda, Massimo

AU - Maher, Elizabeth

AU - Ogino, Shuji

AU - Fuschs, Charles S.

AU - Li, Jin

AU - Hader, Carlos

AU - Makrigiorgos, G. Mike

PY - 2007/9

Y1 - 2007/9

N2 - The need to apply modern technologies to analyze DNA from diverse clinical samples often stumbles on suboptimal sample quality. We developed a simple approach to assess DNA fragmentation in minute clinical samples of widely different origin and the likelihood of success of degradation-tolerant whole genome amplification (restriction and circularization-aided rolling circle amplification, RCA-RCA) and subsequent polymerase chain reaction (PCR). A multiplex PCR amplification of four glyceraldehyde-3-phosphate dehydrogenase amplicons of varying sizes was performed using genomic DNA from clinical samples, followed by size discrimination on agarose gel or fluorescent denaturing high-performance liquid chromatography (dHPLC). RCA-RCA followed by real-time PCR was also performed, for correlation. Even minimal quantities of longer PCR fragments (∼ 300 to 400 bp), visible via high-sensitivity fluorescent dHPLC or agarose gel, were essential for the success of RCA-RCA and subsequent PCR-based assays. dHPLC gave a more accurate correlation between DNA fragmentation and sample quality than agarose gel electrophoresis. Multiplex-PCR-dHPLC predicted correctly the likelihood of assay success in formalin-fixed, paraffin-embedded samples fixed under controlled conditions and of different ages, in laser capture microdissection samples, in tissue print micropeels, and plasma-circulating DNA. Estimates of the percent information retained relative to snap-frozen DNA are derived for real-time PCR analysis. The assay is rapid and convenient and can be used widely to characterize DNA from any clinical sample of unknown quality.

AB - The need to apply modern technologies to analyze DNA from diverse clinical samples often stumbles on suboptimal sample quality. We developed a simple approach to assess DNA fragmentation in minute clinical samples of widely different origin and the likelihood of success of degradation-tolerant whole genome amplification (restriction and circularization-aided rolling circle amplification, RCA-RCA) and subsequent polymerase chain reaction (PCR). A multiplex PCR amplification of four glyceraldehyde-3-phosphate dehydrogenase amplicons of varying sizes was performed using genomic DNA from clinical samples, followed by size discrimination on agarose gel or fluorescent denaturing high-performance liquid chromatography (dHPLC). RCA-RCA followed by real-time PCR was also performed, for correlation. Even minimal quantities of longer PCR fragments (∼ 300 to 400 bp), visible via high-sensitivity fluorescent dHPLC or agarose gel, were essential for the success of RCA-RCA and subsequent PCR-based assays. dHPLC gave a more accurate correlation between DNA fragmentation and sample quality than agarose gel electrophoresis. Multiplex-PCR-dHPLC predicted correctly the likelihood of assay success in formalin-fixed, paraffin-embedded samples fixed under controlled conditions and of different ages, in laser capture microdissection samples, in tissue print micropeels, and plasma-circulating DNA. Estimates of the percent information retained relative to snap-frozen DNA are derived for real-time PCR analysis. The assay is rapid and convenient and can be used widely to characterize DNA from any clinical sample of unknown quality.

UR - http://www.scopus.com/inward/record.url?scp=34548722702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548722702&partnerID=8YFLogxK

U2 - 10.2353/jmoldx.2007.070004

DO - 10.2353/jmoldx.2007.070004

M3 - Article

VL - 9

SP - 441

EP - 451

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 4

ER -